gefitinib 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
tyrosine kinase inhibitors	1282	184475-35-2

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: ZD1839 gefitinib iressa ZD 1839	Gefitinib reversibly inhibits the kinase activity of wild-type and certain activating mutations of EGFR, preventing autophosphorylation of tyrosine residues associated with the receptor, thereby inhibiting further downstream signalling and blocking EGFR-dependent proliferation. Molecular weight: 446.91 Formula: C22H24ClFN4O3 CLOGP: 5.25 LIPINSKI: 1 HAC: 7 HDO: 1 TPSA: 68.74 ALOGS: -4.22 ROTB: 8 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

ZD1839
gefitinib
iressa
ZD 1839

Gefitinib reversibly inhibits the kinase activity of wild-type and certain activating mutations of EGFR, preventing autophosphorylation of tyrosine residues associated with the receptor, thereby inhibiting further downstream signalling and blocking EGFR-dependent proliferation.

Molecular weight: 446.91
Formula: C22H24ClFN4O3
CLOGP: 5.25
LIPINSKI: 1
HAC: 7
HDO: 1
TPSA: 68.74
ALOGS: -4.22
ROTB: 8

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
0.25	g	O

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	2	Benet LZ, Broccatelli F, Oprea TI
S (Water solubility)	0.00 mg/mL	Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine)	2 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	8 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability)	60 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution)	23 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	12 mL/min/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	0.09 %	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	34 hours	Lombardo F, Berellini G, Obach RS

Approvals:

Date	Agency	Company	Orphan
May 5, 2003	FDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Malignant neoplasm progression	1056.49	24.28	375	6260	73212	56212220
Drug resistance	622.13	24.28	185	6450	20357	56265075
Acquired gene mutation	359.99	24.28	66	6569	821	56284611
Metastases to central nervous system	276.50	24.28	88	6547	12048	56273384
EGFR gene mutation	257.09	24.28	42	6593	247	56285185
Interstitial lung disease	251.03	24.28	126	6509	56937	56228495
Hepatic function abnormal	231.29	24.28	102	6533	34456	56250976
Liver disorder	183.39	24.28	94	6541	44276	56241156
Disease progression	165.69	24.28	120	6515	105053	56180379
Malignant transformation	164.93	24.28	30	6605	355	56285077
Diarrhoea	145.32	24.28	264	6371	638243	55647189
Paronychia	134.32	24.28	41	6594	4877	56280555
Lung disorder	108.63	24.28	71	6564	52526	56232906
Metastases to meninges	107.22	24.28	29	6606	2241	56283191
Dermatitis acneiform	80.63	24.28	27	6608	4317	56281115
Gene mutation	61.40	24.28	17	6618	1432	56284000
Metastases to bone	59.96	24.28	34	6601	19474	56265958
Small cell lung cancer	59.46	24.28	17	6618	1609	56283823
Pleural effusion	59.12	24.28	61	6574	85419	56200013
Skin toxicity	54.72	24.28	20	6615	4133	56281299
Metastases to lung	54.70	24.28	27	6608	11691	56273741
Therapy partial responder	39.52	24.28	19	6616	7766	56277666
Metastases to liver	39.36	24.28	27	6608	21559	56263873
Rash	37.35	24.28	135	6500	492912	55792520
Skin disorder	36.76	24.28	28	6607	26281	56259151
Hepatotoxicity	36.74	24.28	30	6605	31123	56254309
Lung adenocarcinoma stage IV	31.91	24.28	7	6628	223	56285209
Metastasis	31.55	24.28	14	6621	4770	56280662
Pneumothorax	30.47	24.28	20	6615	14847	56270585
Leukoencephalopathy	30.35	24.28	13	6622	4069	56281363
Arthralgia	29.81	24.28	11	6624	501658	55783774
Dry skin	29.65	24.28	32	6603	47077	56238355
Lymphangiosis carcinomatosa	28.17	24.28	9	6626	1240	56284192
Pneumonitis	26.38	24.28	25	6610	31539	56253893
Carcinoembryonic antigen increased	25.92	24.28	9	6626	1603	56283829
PRIDE syndrome	25.75	24.28	4	6631	16	56285416

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Malignant neoplasm progression	424.15	23.30	217	4679	78781	31613667
Interstitial lung disease	284.07	23.30	153	4743	61250	31631198
Drug resistance	243.07	23.30	102	4794	23351	31669097
Acquired gene mutation	182.15	23.30	42	4854	1278	31691170
EGFR gene mutation	159.24	23.30	26	4870	110	31692338
Lung disorder	153.13	23.30	82	4814	32230	31660218
Disease progression	109.56	23.30	99	4797	90365	31602083
Metastases to central nervous system	102.29	23.30	40	4856	7596	31684852
Rash	92.37	23.30	133	4763	201353	31491095
Metastases to bone	70.13	23.30	34	4862	10814	31681634
Hepatic function abnormal	65.90	23.30	53	4843	41169	31651279
Diarrhoea	55.38	23.30	148	4748	352261	31340187
Dermatitis acneiform	52.72	23.30	23	4873	5744	31686704
Metastases to meninges	49.94	23.30	15	4881	1284	31691164
Mitochondrial aspartate aminotransferase increased	49.58	23.30	7	4889	7	31692441
Malignant transformation	47.09	23.30	13	4883	824	31691624
Metastases to lung	44.42	23.30	23	4873	8399	31684049
Metastases to pleura	41.14	23.30	10	4886	382	31692066
Liver disorder	40.80	23.30	35	4861	29672	31662776
Metastases to liver	40.59	23.30	25	4871	12702	31679746
Lymphangiosis carcinomatosa	37.80	23.30	11	4885	843	31691605
Paronychia	29.95	23.30	13	4883	3205	31689243
Dehydration	28.32	23.30	59	4837	119052	31573396
Vomiting	28.11	23.30	87	4809	223886	31468562
Malignant pleural effusion	24.69	23.30	9	4887	1405	31691043
Decreased appetite	24.51	23.30	65	4831	153152	31539296
Cystitis haemorrhagic	23.81	23.30	13	4883	5276	31687172

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Malignant neoplasm progression	1105.13	21.14	472	9852	121267	70796853
Drug resistance	756.25	21.14	262	10062	37928	70880192
Acquired gene mutation	497.38	21.14	103	10221	1995	70916125
Interstitial lung disease	461.72	21.14	248	10076	104437	70813683
EGFR gene mutation	389.66	21.14	65	10259	346	70917774
Metastases to central nervous system	327.60	21.14	111	10213	14923	70903197
Hepatic function abnormal	279.59	21.14	154	10170	67842	70850278
Lung disorder	223.11	21.14	134	10190	69350	70848770
Liver disorder	208.76	21.14	123	10201	61445	70856675
Malignant transformation	178.51	21.14	40	10284	1133	70916987
Diarrhoea	163.92	21.14	354	9970	782987	70135133
Disease progression	152.37	21.14	148	10176	156524	70761596
Paronychia	137.55	21.14	48	10276	7026	70911094
Metastases to bone	127.06	21.14	63	10261	22313	70895807
Rash	123.02	21.14	245	10079	510317	70407803
Dermatitis acneiform	122.96	21.14	47	10277	8898	70909222
Metastases to meninges	121.76	21.14	36	10288	3100	70915020
Metastases to lung	80.70	21.14	42	10282	16442	70901678
Small cell lung cancer	69.67	21.14	23	10301	2843	70915277
Pleural effusion	64.91	21.14	88	10236	132776	70785344
Gene mutation	62.23	21.14	20	10304	2271	70915849
Skin toxicity	61.81	21.14	27	10297	7171	70910949
Lymphangiosis carcinomatosa	61.65	21.14	19	10305	1882	70916238
Metastases to liver	58.34	21.14	40	10284	25838	70892282
Mitochondrial aspartate aminotransferase increased	50.00	21.14	7	10317	7	70918113
Metastasis	49.48	21.14	22	10302	6092	70912028
Skin disorder	43.98	21.14	36	10288	30321	70887799
Hepatotoxicity	43.47	21.14	42	10282	43944	70874176
Therapy partial responder	42.40	21.14	25	10299	12449	70905671
Malignant pleural effusion	41.36	21.14	16	10308	3123	70914997
Decreased appetite	40.11	21.14	116	10208	304664	70613456
Cystitis haemorrhagic	39.51	21.14	21	10303	8572	70909548
Metastases to pleura	37.83	21.14	12	10312	1306	70916814
Leukoencephalopathy	36.88	21.14	19	10305	7275	70910845
Arthralgia	36.27	21.14	14	10310	503376	70414744
Pneumothorax	36.08	21.14	30	10294	25816	70892304
Dehydration	33.60	21.14	90	10234	226052	70692068
Lung adenocarcinoma stage IV	31.81	21.14	8	10316	374	70917746
Alanine aminotransferase increased	30.83	21.14	67	10257	147413	70770707
Dry skin	30.29	21.14	39	10285	55892	70862228
Metastases to lymph nodes	30.06	21.14	18	10306	9220	70908900
Carcinoembryonic antigen increased	29.09	21.14	11	10313	2019	70916101
Pneumatosis intestinalis	28.80	21.14	15	10309	5872	70912248
Respiratory failure	27.98	21.14	70	10254	168665	70749455
Lung infiltration	25.91	21.14	23	10301	21601	70896519
Drug hypersensitivity	25.23	21.14	4	10320	262455	70655665
Pain	25.03	21.14	33	10291	628783	70289337
Pneumonia	24.93	21.14	160	10164	596072	70322048
PRIDE syndrome	24.91	21.14	4	10320	16	70918104
Pneumonitis	24.87	21.14	35	10289	54562	70863558
Drug ineffective	24.44	21.14	64	10260	939688	69978432
Peripheral swelling	24.16	21.14	3	10321	236560	70681560
Lung carcinoma cell type unspecified recurrent	23.87	21.14	6	10318	280	70917840
Lung adenocarcinoma	22.50	21.14	14	10310	7676	70910444
Sarcomatoid carcinoma	22.24	21.14	4	10320	35	70918085
Cerebral infarction	21.75	21.14	29	10295	42980	70875140
Vomiting	21.69	21.14	154	10170	592957	70325163
Aspartate aminotransferase increased	21.38	21.14	53	10271	126925	70791195
Acne	21.25	21.14	22	10302	24967	70893153

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	L01EB01	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS ANTINEOPLASTIC AGENTS PROTEIN KINASE INHIBITORS Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors
FDA MoA	N0000175076	Protein Kinase Inhibitors
MeSH PA	D000970	Antineoplastic Agents
MeSH PA	D004791	Enzyme Inhibitors
MeSH PA	D047428	Protein Kinase Inhibitors
FDA EPC	N0000175605	Kinase Inhibitor
CHEBI has role	CHEBI:35610	antineoplastic agents
CHEBI has role	CHEBI:74440	EGFR antagonoists

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Non-small cell lung cancer	indication	254637007	DOID:3908
Non-small cell lung cancer, positive for epidermal growth factor receptor expression	indication	426964009
Fibrosis of lung	contraindication	51615001	DOID:3770
Acute nephropathy	contraindication	58574008
Interstitial pneumonia	contraindication	64667001
Disease of liver	contraindication	235856003	DOID:409
Pregnancy, function	contraindication	289908002
Breastfeeding (mother)	contraindication	413712001
Non-small cell lung cancer, negative for epidermal growth factor receptor expression	contraindication	427038005

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	7.65	Basic
pKa2	5.8	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Exclusivity date	Description
250MG	IRESSA	ASTRAZENECA	N206995	July 13, 2015	RX	TABLET	ORAL	July 13, 2022	FOR THE FIRST-LINE TREATMENT OF PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WHOSE TUMORS HAVE EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) EXON 19 DELETIONS OR EXON 21 (L858R) SUBSTITUTION MUTATIONS AS DETECTED BY AN FDA-APPROVED TEST

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Epidermal growth factor receptor	Kinase	P00533	EGFR_HUMAN	INHIBITOR	Ki	9.40	CHEMBL	CHEMBL
Ephrin type-A receptor 3	Kinase	P29320	EPHA3_HUMAN		Kd	5.26	CHEMBL
Tyrosine-protein kinase FRK	Kinase	P42685	FRK_HUMAN		Kd	5.70	CHEMBL
ATP-binding cassette sub-family G member 2	Transporter	Q9UNQ0	ABCG2_HUMAN		IC50	5.96	CHEMBL
Tyrosine-protein kinase ABL1	Kinase	P00519	ABL1_HUMAN		Kd	6.64	CHEMBL
Mast/stem cell growth factor receptor Kit	Kinase	P10721	KIT_HUMAN		Kd	5.74	CHEMBL
Tyrosine-protein kinase Lck	Kinase	P06239	LCK_HUMAN		Kd	6.20	CHEMBL
Serine/threonine-protein kinase B-raf	Kinase	P15056	BRAF_HUMAN		IC50	5.70	CHEMBL
Receptor-type tyrosine-protein kinase FLT3	Kinase	P36888	FLT3_HUMAN		Kd	6	CHEMBL
Proto-oncogene tyrosine-protein kinase receptor Ret	Kinase	P07949	RET_HUMAN		IC50	5.77	CHEMBL
Vascular endothelial growth factor receptor 2	Kinase	P35968	VGFR2_HUMAN		IC50	5.72	CHEMBL
Receptor tyrosine-protein kinase erbB-2	Kinase	P04626	ERBB2_HUMAN		Kd	5.96	CHEMBL
Phosphorylase b kinase gamma catalytic chain, liver/testis isoform	Kinase	P15735	PHKG2_HUMAN		Kd	5.57	CHEMBL
Death-associated protein kinase 3	Kinase	O43293	DAPK3_HUMAN		Kd	5.24	CHEMBL
Tyrosine-protein kinase HCK	Kinase	P08631	HCK_HUMAN		Kd	5.36	CHEMBL
Receptor tyrosine-protein kinase erbB-4	Kinase	Q15303	ERBB4_HUMAN		Kd	6.39	CHEMBL
Mitogen-activated protein kinase 10	Kinase	P53779	MK10_HUMAN		Kd	5.64	CHEMBL
Myosin light chain kinase 2, skeletal/cardiac muscle	Kinase	Q9H1R3	MYLK2_HUMAN		Kd	5.72	CHEMBL
Ephrin type-A receptor 8	Kinase	P29322	EPHA8_HUMAN		Kd	5.74	CHEMBL
Hepatocyte growth factor receptor	Kinase	P08581	MET_HUMAN		Kd	5.46	CHEMBL
Tyrosine-protein kinase Lyn	Kinase	P07948	LYN_HUMAN		Kd	6	CHEMBL
Phosphorylase b kinase gamma catalytic chain, skeletal muscle/heart isoform	Kinase	Q16816	PHKG1_HUMAN		Kd	5.43	CHEMBL
Serine/threonine-protein kinase 17B	Kinase	O94768	ST17B_HUMAN		Kd	5.42	CHEMBL
Serine/threonine-protein kinase 10	Kinase	O94804	STK10_HUMAN		Kd	6.33	CHEMBL
Abelson tyrosine-protein kinase 2	Kinase	P42684	ABL2_HUMAN		Kd	5.80	CHEMBL
Ephrin type-A receptor 5	Kinase	P54756	EPHA5_HUMAN		Kd	5.82	CHEMBL
Serine/threonine-protein kinase 17A	Kinase	Q9UEE5	ST17A_HUMAN		Kd	5.70	CHEMBL
Ephrin type-A receptor 6	Kinase	Q9UF33	EPHA6_HUMAN		Kd	6.23	CHEMBL
TRAF2 and NCK-interacting protein kinase	Kinase	Q9UKE5	TNIK_HUMAN		Kd	5.16	CHEMBL
Casein kinase I isoform epsilon	Kinase	P49674	KC1E_HUMAN		Kd	6.37	CHEMBL
Tyrosine-protein kinase Fgr	Kinase	P09769	FGR_HUMAN		Kd	5.59	CHEMBL
Serine/threonine-protein kinase 36	Kinase	Q9NRP7	STK36_HUMAN		Kd	5.24	CHEMBL
Cyclin-G-associated kinase	Kinase	O14976	GAK_HUMAN		Kd	8.15	CHEMBL
Receptor-interacting serine/threonine-protein kinase 2	Kinase	O43353	RIPK2_HUMAN		Kd	6.28	CHEMBL
Ephrin type-B receptor 1	Kinase	P54762	EPHB1_HUMAN		Kd	5.89	CHEMBL
Activated CDC42 kinase 1	Kinase	Q07912	ACK1_HUMAN		IC50	5.64	CHEMBL
STE20-like serine/threonine-protein kinase	Kinase	Q9H2G2	SLK_HUMAN		Kd	6.04	CHEMBL
MAP kinase-interacting serine/threonine-protein kinase 2	Kinase	Q9HBH9	MKNK2_HUMAN		Kd	6.44	CHEMBL
Mitogen-activated protein kinase 9	Kinase	P45984	MK09_HUMAN		Kd	5.85	CHEMBL
Ephrin type-B receptor 4	Kinase	P54760	EPHB4_HUMAN		Kd	5.60	CHEMBL
Protein-tyrosine kinase 6	Kinase	Q13882	PTK6_HUMAN		IC50	6.01	CHEMBL
Tyrosine-protein kinase receptor UFO	Kinase	P30530	UFO_HUMAN		Kd	5.74	CHEMBL
Cyclin-dependent kinase 7	Kinase	P50613	CDK7_HUMAN		Kd	6.21	CHEMBL
Serine/threonine-protein kinase D1	Kinase	Q15139	KPCD1_HUMAN		Kd	5.46	CHEMBL
Serine/threonine-protein kinase DCLK3	Kinase	Q9C098	DCLK3_HUMAN		Kd	5.54	CHEMBL
NUAK family SNF1-like kinase 2	Kinase	Q9H093	NUAK2_HUMAN		Kd	5.34	CHEMBL
Casein kinase I isoform delta	Kinase	P48730	KC1D_HUMAN		Kd	5.49	CHEMBL
Tyrosine-protein kinase TXK	Kinase	P42681	TXK_HUMAN		Kd	5.22	CHEMBL
MAP kinase-interacting serine/threonine-protein kinase 1	Kinase	Q9BUB5	MKNK1_HUMAN		Kd	6.54	CHEMBL
Serine/threonine-protein kinase NLK	Kinase	Q9UBE8	NLK_HUMAN		Kd	5.38	CHEMBL
Interleukin-1 receptor-associated kinase 3	Kinase	Q9Y616	IRAK3_HUMAN		Kd	5.82	CHEMBL
Serine/threonine-protein kinase SIK2	Kinase	Q9H0K1	SIK2_HUMAN		Kd	5.68	CHEMBL
Myotonin-protein kinase	Kinase	Q09013	DMPK_HUMAN		Kd	5.16	CHEMBL
Leukocyte tyrosine kinase receptor	Kinase	P29376	LTK_HUMAN		Kd	5.26	CHEMBL
Serine/threonine-protein kinase pim-3	Kinase	Q86V86	PIM3_HUMAN		Kd	5.24	CHEMBL
Tyrosine-protein kinase Blk	Kinase	P51451	BLK_HUMAN		Kd	5.92	CHEMBL
Citron Rho-interacting kinase	Kinase	O14578	CTRO_HUMAN		Kd	5.89	CHEMBL
Ephrin type-A receptor 1	Kinase	P21709	EPHA1_HUMAN		Kd	5.40	CHEMBL
Mitogen-activated protein kinase 6	Kinase	Q16659	MK06_HUMAN		Kd	5.80	CHEMBL
Mitogen-activated protein kinase 4	Kinase	P31152	MK04_HUMAN		Kd	5.51	CHEMBL
Ribosomal protein S6 kinase alpha-4	Kinase	O75676	KS6A4_HUMAN		Kd	5.92	CHEMBL
Misshapen-like kinase 1	Kinase	Q8N4C8	MINK1_HUMAN		Kd	5.74	CHEMBL
Interleukin-1 receptor-associated kinase 4	Kinase	Q9NWZ3	IRAK4_HUMAN		Kd	6.27	CHEMBL
Serine/threonine-protein kinase Chk2	Kinase	O96017	CHK2_HUMAN		Kd	6.10	CHEMBL
Ephrin type-B receptor 6	Kinase	O15197	EPHB6_HUMAN		Kd	5.49	CHEMBL
Homeodomain-interacting protein kinase 4	Kinase	Q8NE63	HIPK4_HUMAN		Kd	6.51	CHEMBL
Interleukin-1 receptor-associated kinase 1	Kinase	P51617	IRAK1_HUMAN		Kd	7.16	CHEMBL
Mitogen-activated protein kinase kinase kinase 2	Kinase	Q9Y2U5	M3K2_HUMAN		Kd	5.48	CHEMBL
Mitogen-activated protein kinase kinase kinase 3	Kinase	Q99759	M3K3_HUMAN		Kd	5.68	CHEMBL
Mitogen-activated protein kinase kinase kinase 19	Kinase	Q56UN5	M3K19_HUMAN		Kd	6.62	CHEMBL
Receptor tyrosine-protein kinase erbB-3	Kinase	P21860	ERBB3_HUMAN		Kd	6.10	CHEMBL
Serine/threonine-protein kinase SBK1	Kinase	Q52WX2	SBK1_HUMAN		Kd	6.25	CHEMBL
Phosphatidylinositol 5-phosphate 4-kinase type-2 gamma	Kinase	Q8TBX8	PI42C_HUMAN		Kd	5.12	CHEMBL
Dual specificity mitogen-activated protein kinase kinase 5	Kinase	Q13163	MP2K5_HUMAN		Kd	6.22	CHEMBL
Ferrochelatase, mitochondrial	Enzyme	P22830	HEMH_HUMAN		Kd	5.17	CHEMBL
Receptor-interacting serine/threonine-protein kinase 3	Kinase	Q9Y572	RIPK3_HUMAN		Kd	5.57	CHEMBL
Acyl-CoA dehydrogenase family member 10	Enzyme	Q6JQN1	ACD10_HUMAN		Kd	4.47	CHEMBL
Transcription factor p65	Transcription factor	Q04206	TF65_HUMAN		IC50	7.26	CHEMBL
Beta-secretase 1	Enzyme	P56817	BACE1_HUMAN		IC50	4.70	CHEMBL
Proto-oncogene tyrosine-protein kinase Src	Kinase	P12931	SRC_HUMAN		Kd	5.42	SCIENTIFIC LITERATURE
Serine/threonine-protein kinase ULK3	Kinase		ULK3_MOUSE		Kd	5.85	CHEMBL
Tubulin alpha-1A chain	Structural		TBA1A_RAT		Kd	6.39	CHEMBL
Cruzipain	Enzyme		CYSP_TRYCR		IC50	4.06	CHEMBL
Quinolone resistance protein NorA	Transporter		NORA_STAAU		IC50	5.01	CHEMBL

External reference:

ID	Source
4021392	VUID
N0000148810	NUI
D01977	KEGG_DRUG
4021392	VANDF
C1122962	UMLSCUI
CHEBI:49668	CHEBI
IRE	PDB_CHEM_ID
CHEMBL939	ChEMBL_ID
D000077156	MESH_DESCRIPTOR_UI
DB00317	DRUGBANK_ID
4941	IUPHAR_LIGAND_ID
8204	INN_ID
S65743JHBS	UNII
123631	PUBCHEM_CID
281883	RXNORM
17257	MMSL
46712	MMSL
d04868	MMSL
009981	NDDF
398685009	SNOMEDCT_US
407100002	SNOMEDCT_US

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
IRESSA	HUMAN PRESCRIPTION DRUG LABEL	1	0310-0482	TABLET, COATED	250 mg	ORAL	NDA	28 sections
IRESSA	HUMAN PRESCRIPTION DRUG LABEL	1	0310-0482	TABLET, COATED	250 mg	ORAL	NDA	28 sections